PEDIATRIC PSORIASIS | CELGENE PPSO-003 | PHASE III Status: RECRUITING Drug: Apremilast – CC-10004 Timeline: 19 visits over 66 weeks Detailed Description This is a phase 3, multi-centre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of apremilast (CC-10004) in pediatric subjects from 6 to 17 years of age with moderate to severe plaque...Continue Reading
PRURIGO NODULARIS | SANOFI GENZYME EFC16460 | PHASE III Status: RECRUITING Drug: SAR231893 / REGN668 Timeline: TBD Detailed Description This is a randomized, double-blind, placebo-controlled, multi-centre, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are...Continue Reading
PEDIATRIC ATOPIC DERMATITIS | M16-813 | PHASE II Status: Drug: Timeline: Detailed Description Eligibility Exclusions If you’re interested in participating, please SEND US AN EMAIL AND/OR CONTACT US and our research team will be in touch.Continue Reading
ATOPIC DERMATITIS | PFIZER B7451029 | PHASE III Status: FULLY RECRUITED Drug: PF-04965842 & DUPILUMAB Timeline: 11 visits over 24 weeks Detailed Description This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of PF-04965842 and Dupilumab in pediatric subjects from 6 to 17 years of age with moderate...Continue Reading
ATOPIC DERMATITIS | PFIZER B7451014 | PHASE III Status: FULLY RECRUITED Drug: PF-04965842 Timeline: 56 weeks Detailed Description This trial will evaluate and compare the maintenance of effect of two doses of PF-04965842 (200 mg and 100mg once daily) and placebo in subjects aged 12 and above with moderate to severe atopic dermatitis who respond to...Continue Reading
PEDIATRIC ATOPIC DERMATITIS | LEO LP0162 | PHASE III Status: FULLY RECRUITED Drug: Tralokinumab Timeline: 29 visits in 52 weeks Detailed Description This is a randomized, double-blinded, placebo-controlled trial in adolescent subjects aged 12 to 17 years with moderate to severe atopic dermatitis. Inclusion Informed consent Age 12 to 17 years old Body Weight at baseline...Continue Reading
